News

Tamaris is a randomised, double blind, placebo controlled study designed to evaluate the safety and efficacy of NV1FGF in patients with critical limb ischemia and skin lesions who

Most recently, McElroy has worked with Chiltern International for over two years as the executive director of Strategic Development, Americas. Before joining Chiltern, he served as the vice

OctoPlus said that the undisclosed contract value will make a material contribution to its’ annual revenues. As per the contract terms, OctoPlus is expected to perform clinical manufacturing

The Promus Element Stent features a new Platinum chromium (PtCr) alloy and new stent design, which combine to offer greater radial strength and flexibility while reducing stent recoil.

Novartis claimed that the FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. Gilenya belongs to a new class

Catalyst Pharma is currently conducting a number of non-clinical safety and efficacy studies with CPP-115 to support various indications and expects to file an IND with respect to

The MHRA inspection was conducted on the GMP side to determine whether Almac’s IXRS integrated phone and web response system was able to adequately ensure that expired products

Winton will report to Bart Peterson, senior vice president, Corporate Affairs and Communications. Winton is expected to take up the responsibility for Communications across Lilly, including oversight of

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio – CUSHING’S disease), a randomised study to evaluate a medical therapy in patients with Cushing’s disease, is part of a large-scale global clinical